Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Special Feature Articles - Most Recent
    • Special Features
    • Colloquia
    • Collected Articles
    • PNAS Classics
    • List of Issues
  • Front Matter
    • Front Matter Portal
    • Journal Club
  • News
    • For the Press
    • This Week In PNAS
    • PNAS in the News
  • Podcasts
  • Authors
    • Information for Authors
    • Editorial and Journal Policies
    • Submission Procedures
    • Fees and Licenses
  • Submit
  • Submit
  • About
    • Editorial Board
    • PNAS Staff
    • FAQ
    • Accessibility Statement
    • Rights and Permissions
    • Site Map
  • Contact
  • Journal Club
  • Subscribe
    • Subscription Rates
    • Subscriptions FAQ
    • Open Access
    • Recommend PNAS to Your Librarian

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Home
Home
  • Log in
  • My Cart

Advanced Search

  • Home
  • Articles
    • Current
    • Special Feature Articles - Most Recent
    • Special Features
    • Colloquia
    • Collected Articles
    • PNAS Classics
    • List of Issues
  • Front Matter
    • Front Matter Portal
    • Journal Club
  • News
    • For the Press
    • This Week In PNAS
    • PNAS in the News
  • Podcasts
  • Authors
    • Information for Authors
    • Editorial and Journal Policies
    • Submission Procedures
    • Fees and Licenses
  • Submit
Research Article

β2-Glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: Loss of inhibition by clipped β2-glycoprotein I

Tong Shi, G. Michael Iverson, Jian C. Qi, Keith A. Cockerill, Matthew D. Linnik, Pamela Konecny, and Steven A. Krilis
  1. *Departments of Medicine and Immunology, Allergy, and Infectious Diseases, St. George Hospital, University of New South Wales, Kogarah 2217, Australia; and †La Jolla Pharmaceutical Company, San Diego, CA 92121

See allHide authors and affiliations

PNAS March 16, 2004 101 (11) 3939-3944; https://doi.org/10.1073/pnas.0400281101
Tong Shi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Michael Iverson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jian C. Qi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keith A. Cockerill
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew D. Linnik
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pamela Konecny
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven A. Krilis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  1. Communicated by K. Frank Austen, Harvard Medical School, Boston, MA, January 13, 2004 (received for review December 3, 2003)

  • Article
  • Figures & SI
  • Info & Metrics
  • PDF
Loading

Abstract

Activation of factor XI (FXI) by thrombin in vivo plays a role in coagulation by providing an important positive feedback mechanism for additional thrombin generation. FXI is activated in vitro by thrombin, or FXIIa in the presence of dextran sulfate. In this report, we investigated the effect of β2-glycoprotein I (β2GPI) on the activation of FXI. β2GPI bound FXI in vitro and inhibited its activation to FXIa by thrombin and FXIIa. The affinity of the interaction between β2GPI and FXI was equivalent to the interaction between FXI and high molecular weight kininogen. Inhibition of FXI activation occurred with lower concentrations of β2GPI than found in human plasma. Proteolytic clipping of β2GPI by plasmin abolished its inhibition of FXI activation. The results suggest a mechanism of regulation whereby physiological concentrations of β2GPI may attenuate thrombin generation in vivo by inhibition of FXI activation. Plasmin cleavage of β2GPI provides a negative feedback that counteracts its inhibition of FXI activation.

β2 -Glycoprotein I (β2GPI) (also known as Apolipoprotein H, Apo H) is a plasma glycoprotein of 50 kDa that circulates in plasma at ≈4 μM. β2GPI has 326 amino acids and consists of repeated sequences in a form typical of the complement control protein (CCP) module. Individual modules are also known as short consensus repeats (SCR), a key feature of which is disulphide bridges joining the first to third and second to fourth cysteine residues (1-4). The first four domains have four cysteines and ≈60 aa each. The fifth domain contains an extra disulphide bond and C-terminal extension of 20 aa where the terminating cysteine forms a disulphide bridge (5). β2GPI has affinity for negative charged macromolecules such as anionic phospholipids and proteoglycans. Within domain 5 the region Cys-281-Cys-288 is critical for phospholipid and heparin binding and is highly conserved (6-10). The C-terminal extension in the fifth domain is surface exposed and susceptible to proteolytic cleavage (9). We have previously reported that β2GPI is proteolytically clipped between Lys-317 and Thr-318 in the fifth domain abolishing binding to anionic phospholipids (7). The cleavage at Lys-317-Thr-318 is generated in vitro by plasmin and at low efficiency by activated factor X (FXa) and in vivo in pathological states of increased fibrinolysis (11-13).

β2GPI is the primary target antigen recognized by autoantibodies in patients with the antiphospholipid syndrome (APS) (14, 15). APS is characterized by recurrent thrombotic events, miscarriages, thrombocytopenia, and the presence of antiphospholipid antibodies (6, 16, 17). Binding of autoantibodies to β2GPI is now generally accepted as an important feature of APS, and a number of studies have shown there is a significant correlation between thrombotic manifestations and the presence of anti-β2GPI antibodies (17). Although the physiological function of β2GPI in normal individuals remains to be elucidated, plasma from β2GPI knockout mice exhibits impaired thrombin generation in vitro (18). β2GPI has both pro- and anticoagulant properties when examined in vitro. It inhibits the generation of FXa in the presence of activated platelets (19), prothrombinase activity (20), and the ADP-mediated aggregation of platelets (21). The in vitro anticoagulant activity of activated protein C (APC) is also inhibited by β2GPI (22). Furthermore, it has been proposed that β2GPI can influence the activity of lipoprotein lipase (23) and apoptosis (24). The association of β2GPI with multiple procoagulant and anticoagulant effects may result from its ability to bind anionic phospholipids on activated platelets and endothelial cells. β2GPI may act by competing with coagulation factors for phospholipid surfaces (17).

The contact pathway of coagulation is initiated with activation of FXII by contact with negatively charged surfaces (25). FXIIa in turn cleaves FXI to FXIa in the presence of high molecular weight kininogen (HK) and prekallikreine (PK). Although previous studies showed that β2GPI inhibits the phospholipid mediated autoactivation of FXII (26) and the contact activation pathway of coagulation (27), the mechanism by which β2GPI acts on this pathway has not been determined. We now report that β2GPI binds FXI in vitro and inhibits activation to FXIa by thrombin and FXIIa. In vivo activation of FXI by thrombin is thought to be an important mechanism by which coagulation is accelerated via components of the contact activation pathway. Thus, β2GPI may attenuate the contact activation pathway by inhibiting activation of FXI by thrombin. Moreover, because β2GPI is the dominant autoantigen in patients with APS, dysregulation of this pathway by autoantibodies may be an important mechanism for thrombosis in patients with APS.

Experimental Procedures

Proteins. Plasma-derived FXI, FXIa, HK (single chain), and FXIIa were purchased from Calbiochem-Novabiochem. Substrates S2366 and S2302 were obtained from Chromogenix Instrumentation Laboratory (Milan, Italy). Spectrozyme TH was acquired from American Diagnostica (Greenwich, CT). Kaolin was purchased from Gradipore (Sydney). Hirudin, thrombin, polybrene (Hexadimethrine Bromide), human serum albumin (HSA), BSA, plasmin, phosphatidylserine (PS), and dextran sulfate (DS) (500,000 Da) were purchased from Sigma. β2GPI-deficient plasma was purchased from Affinity Biologicals (Ancaster, ON, Canada). Plasma-derived native β2GPI (nβ2GPI) was purchased from Haematologic Technologies (Essex Junction, VT) or purified in our laboratory by using cardiolipin affinity chromatography as described (14) or by a sequential protocol with perchloric acid precipitation (28), cation exchange chromatography (14), heparin affinity chromatography (28), and gel filtration with Sephacryl S-300. A preparation of nβ2GPI proteolytically clipped by plasmin at Lys-317-Thr-318 was generated as described (10). Recombinant human β2GPI (rhβ2GPI) was produced as described (9, 29).

Methods. Radiolabeling of FXI or rhβ2GPI with 125iodine. FXI and rhβ2GPI were radiolabeled with 125iodine by using the IODOGENE method (IODO-Beads, Pierce) according to the manufacturer's instructions.

Protein determination. Concentrations of 125I-FXI and 125I-rhβ2GPI were determined by using a Micro BCA protein assay kit (Pierce) according to the instructions provided by the manufacturer.

Specific radioactivity. Specific radioactivity was determined as described by Baird and Walsh (30). The specific activity of 125I-FXI was 2.12 × 1018 cpm/mol and that of 125I-rhβ2GPI was 1.36 × 1018cpm/mol. SDS/PAGE analysis of the iodinated proteins revealed only one radioactive band, indicating that there was no contamination of FXI with FXIa.

Binding of 125I-FXI to native and recombinant β2GPI. Binding of 125I-FXI to immobilized rhβ2GPI was performed by using Lockwell microtiter plates (Nunc) as described (31). The microtiter wells were coated with 100 μl of nβ2GPI, rhβ2GPI, or HSA (3.12-200 nM) by incubation overnight at 4°C. Plates were washed five times with PBS/0.1%Tween-20 (PBST) by using an automated microplate washer (Beckman Coulter). The wells were blocked with 2% BSA/PBST for 2 h at 25°C and then washed five times with PBST and five times with PBS. One hundred microliters of 125I-FXI (280 pM) in 0.5%BSA/PBS was added to individual wells and incubated for 4-5 h at 25°C. The wells were washed five times with 0.5% BSA/PBS, air dried, and counted in a γ counter. The number of cpm bound were measured and converted to fmol of FXI bound.

Saturation binding of 125I-FXI to β2GPI and HK. Saturation binding of 125I-FXI to immobilized β2GPI or HK (single chain) was performed by using Lockwell microtiter plates. The wells were coated with 100 μl of rhβ2GPI, nβ2GPI, HK, or BSA (100 nM) by incubation overnight at 4°C. The plate was washed as described above, then 100 μl of various concentrations (0.08-40 nM) of 125I-FXI was added and processed as above. A dissociation constant (K d) was calculated by nonlinear regression (graphpad prism 3.03, GraphPad, San Diego).

Competitive inhibition of 125I-FXI binding to immobilized rhβ2GPI by using fluid phase β2GPI. Effects of nβ2GPI and rhβ2GPI on the binding of 125I-FXI to rhβ2GPI were studied by using Lockwell microtiter plates, the wells of which were coated with 100 μl of rhβ2GPI (50 nM) by incubation overnight at 4°C. The wells were washed and blocked as described above, then 50 μl of either β2GPI or BSA (1.3 nM-20 μM in 0.5% BSA/PBS) was added with 50 μl of 125I-FXI (560 pM) and the wells were incubated 4-5 h at 25°C. The wells were thoroughly washed with 0.5% BSA/PBS, air dried, and counted in a γ counter. The number of cpm bound were measured and converted to percentage of total binding by dividing by the cpm bound in the absence of β2GPI competitor. The IC50 was calculated by nonlinear regression (one site binding model, graphpad prism 3.03).

Amidolytic assay of thrombin, FXIa, and FXIIa in the presence of β2GPI. To determine whether β2GPI affects the amidolytic assay of thrombin, FXIIa, or FXIa, incubations were carried out by using the chromogenic substrates Spectrozyme TH, S2302, and S2366 in the presence of thrombin, FXIIa, or FXIa, respectively. Briefly, thrombin (2 nM), FXIIa (20 nM), or FXIa (0.83 nM) was incubated with β2GPI or BSA (10 μM) for 5 min at 37°C. Incubation mixtures were then diluted 1:5 with TBSA (50 mM Tris·HCl/150 mM NaCl/0.1% BSA, pH 7.6) and 100 μl of each substrate (Spectrozyme TH, 0.50 mM; S2302, 0.24 mM; and S2366, 1.2 mM) was added to 100 μl of the incubation mixture. The reactions were incubated for 1 h at 25°C, and the optical density was measured at 405 nm by using a Microplate Scanning Spectrophotometer (Bio-Tek Instruments, Winooski, VT).

Activation of FXI by thrombin or FXIIa in the presence of DS. Activation of FXI by thrombin or FXIIa was carried out in TBSA with various concentrations of DS (500,000 Da) as described (32, 33), with some modifications. Briefly, FXI (60 nM) was mixed with rhβ2GPI or BSA (1 μM) and various concentrations of DS (0-5 μg/ml) in TBSA. The mixtures were then incubated for 5 min at 37°C, followed by addition of thrombin (2 nM) or FXIIa (2 nM) and incubation for 5-10 min at 37°C. Reactions were stopped by chilling on ice and diluting 1:5 with TBS. For the reactions using thrombin as activator, hirudin (final concentration, 25 units/ml) was added to quench thrombin activity. For the reactions using FXIIa as activator, polybrene (final concentration, 200 μg/ml) was added to neutralize the DS. One hundred-microliter aliquots of each reaction mixture were dispensed into individual microtiter wells and mixed with 100 μl of S2366 (1.2 mM). The optical density was measured at 405 nm by using a Microplate Scanning Spectrophotometer. The amount of FXIa generated was derived from a standard curve constructed with known concentrations of FXIa. There was a linear correlation between OD405 and the amount of FXIa that was 0.06-0.32 pmol (r 2 = 0.9984) with thrombin as activator and 0.02-0.1 pmol (r 2 = 0.9950) with FXIIa as activator.

Activation of FXI by thrombin or FXIIa: Effect of rhβ2GPI. Activation of FXI by thrombin or FXIIa was carried out in TBSA as described by Baglia and Walsh (32) with some modifications. Briefly, FXI (60 nM), DS (1 μg/ml), and various concentrations of rhβ2GPI or BSA (0.016-10 μM) in TBSA were mixed together and incubated for 5 min at 37°C, followed by the addition of thrombin (2 nM) or FXIIa (2 nM) and incubation for a further 5-10 min at 37°C. Reaction mixtures and results were treated as described above. Data fitted a one site binding model, and IC50 was calculated by nonlinear regression (graphpad prism 3.03).

Activation of FXI by thrombin: Effect of nβ2GPI and clipped (c) nβ2GPI. Because β2GPI proteolytically cleaved between Lys-317 and Thr-318 abolishes its anionic phospholipid binding, we assessed the binding of cnβ2GPI to FXI and its effect on thrombin induced activation of FXI. Binding of 125I-FXI (25 nM) to immobilized intact and cnβ2GPI (100 nM) was performed as indicated above. Activation of FXI by thrombin in the presence of nβ2GPI or cnβ2GPI (1 μM) and quantitation of generated FXIa was performed as described above.

Activation of 125I-FXI in β2GPI-deficient human plasma. Activation of FXI was assessed in human plasma deficient in β2GPI in the presence of kaolin, which activates FXII. Activation of FXI was assessed by a semiquantitative analysis of 125I-FXIa according to the protocol described by Brunnee et al. (34). FXI was radiolabeled with 125Iodine as described above to a specific activity of 5.5 × 1016 cpm/mol. β2GPI-deficient human plasma was reconstituted by the addition of rhβ2GPI or BSA to a final concentration of 1.5 μM, then 125I-FXI was added to the reconstituted plasma at a final concentration of 2 nM. The mixtures were incubated for 1 min at 37°C followed by adding an equal volume of Kaolin diluted 2-fold in Tris·HCl buffer (50 mM Tris·HCl/150 mM NaCl, pH 7.6). The mixtures were incubated at 37°C, and at defined time points, 5-μl aliquots were removed and the reaction was stopped by snap freezing the samples. Aliquots at each time point were snap thawed into SDS/PAGE (4-12%) and run under reducing conditions to resolve 125I-FXI and 125I-FXIa heavy and light chains (NuPAGE, Invitrogen). The gel was dried under vacuum for 45-60 min at 70°C (543 Gel Dryer, Bio-Rad), and autoradiography was performed with Kodak BioMax MS film (Amersham Pharmacia) with a Kodak regular X-OMATIC intensifying screen. The film was developed, and densitometry was performed with a Bio-Rad Gel Doc 2000 analysis system. The relative intensity of the bands was calculated from the areas under the peaks on plots of optical density versus migration distance. The amount of 125I-FXIa (heavy plus light chains) was derived from a standard curve constructed with known concentrations of 125I-FXI (r 2 = 0.976).

Saturation binding of 125I-rhβ2GPI to DS and an anti-β2GPI antibody. Saturation binding of 125I-rhβ2GPI to immobilized DS and anti-β2GPI antibody (moAb1) (35) was performed by using Lockwell microtiter plates, the wells of which were coated with 100 μl of moAb1, DS, or BSA (100 nM) by incubation overnight at 4°C. The plate was washed five times with PBS and residual binding sites in the wells were blocked with 2% BSA/PBS for 2 h at 25°C. The plate was washed five times with PBS. One hundred microliters of 125I-rhβ2GPI (1.56-200 nM) in 0.5% BSA/PBS was added to individual wells and incubated for 4 h at 25°C. The wells were thoroughly washed with 0.5% BSA/PBS, air dried, and counted in a γ counter. The number of cpm were measured and converted to pmol of the rhβ2GPI bound. The K d was calculated by nonlinear regression (graphpad prism 3.03).

Binding of 125I-rhβ2GPI to PS or DS. 125I-rhβ2GPI (20 nM) binding to immobilized PS, BSA, or DS was performed by using Lockwell microtiter plates, the wells of which were coated with 100 μl of PS (5 μg/ml), DS (5 μg/ml), or BSA (5 μg/ml) by incubation overnight at 4°C. The plate was then processed as indicated above for 125I-rhβ2GPI binding to DS. The number of cpm bound were measured and converted to pmol of β2GPI bound.

Statistical analysis. Data are expressed as mean ± SD. Differences between groups were evaluated by using Student's t test.

Results

FXI Binds Immobilized Native and Recombinant β2GPI. 125I-FXI bound to rhβ2GPI, nβ2GPI, and HK (data not shown) in a dose-dependent manner, reaching a plateau at 50-100 nM of protein (Fig. 1).

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Binding of 125I-FXI to rhβ2GPI and nβ2GPI. A constant concentration of 125I-FXI was incubated in microtiter wells that were coated with serial dilutions of rhβ2GPI (▴), nβ2GPI (▾), or BSA (▪). The amount of 125I-FXI binding to immobilized proteins was determined as described in Methods.

FXI circulates in plasma as a noncovalent complex with HK (36). Our preliminary experiments showed that the amount of 125I-FXI binding to HK was higher than to β2GPI, so we carried out saturation binding experiments to compare the capacity of 125I-FXI binding to HK or β2GPI. 125I-FXI bound each protein coated onto the plate in a saturable manner. The K d of 125I-FXI binding to HK was 15.43 ± 1.00 × 10-9 (M) and B max 0.73 ± 0.043 × 10-12 (mol) similar to that of rhβ2GPI and nβ2GPI 12.93 ± 4.78 × 10-9 (M) and B max 0.24 ± 0.089 × 10-12 (mol) and 11.65 ± 4.87 × 10-9 (M) and B max 0.22 ± 0.096 × 10-12 (mol), respectively (P = 0.5 and 0.39, respectively).

β2GPI Inhibits Binding of FXI to Immobilized β2GPI. Binding of 125I-FXI to rhβ2GPI was competitively inhibited in a dose-dependent manner by rhβ2GPI and nβ2GPI with IC50 values of 0.167 and 0.115 μM, respectively (Fig. 2).

Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.

Inhibitory effects of rhβ2GPI and nβ2GPI on binding of 125I-FXI to rhβ2GPI. A constant concentration of 125I-FXI was incubated with serial dilutions of rhβ2GPI (▴), nβ2GPI (▾), or BSA (▪) in wells of microtiter plates coated with rhβ2GPI. The number of cpm bound were converted to percentage of total binding by dividing by the cpm bound in the absence of β2GPI competitors.

rhβ2GPI Inhibits Activation of FXI in the Presence of DS. The observation that FXI bound to β2GPI led us to evaluate the effects of β2GPI on activation of FXI by thrombin and FXIIa. In the presence of DS, FXI can be activated by FXIIa as well as by thrombin (32,33). The optimal concentration of DS for activation of FXI was 1-2 μg/ml (data not shown).

β2GPI inhibited FXI activation by thrombin and FXIIa (Fig. 3) with an IC50 of 1.39 and 0.79 μM, respectively. In the absence of inhibitor, 0.170 and 0.058 pmol of FXIa was generated with thrombin and FXIIa, respectively.

Fig. 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 3.

β2GPI dose-dependent inhibitory effect on the activation of FXI by thrombin and FXIIa in the presence of DS. Data are expressed as percentage of FXIa generated in the absence of inhibitor. ▪, Thrombin; □, FXIIa as activator.

β2GPI did not influence the enzymatic activity of FXIIa, thrombin, or FXIa in the amidolytic assay with their respective specific chromogenic substrates (data not shown).

β2GPI Proteolytically Clipped at Lys-317-Thr-318 Binds FXI but Does Not Inhibit Its Activation by Thrombin. To determine whether the cnβ2GPI bound FXI as efficiently as nβ2GPI, we used binding experiments with a constant concentration of 125I-FXI (25 nM) added to wells coated with cnβ2GPI or nβ2GPI. FXI bound to nβ2GPI as efficiently as it did to cnβ2GPI (P = 0.9; n = 6) (Fig. 4A ). The observation that cnβ2GPI bound FXI led us to assess the activation of FXI by thrombin in the presence of cnβ2GPI. The clipped preparation did not cause any inhibition, whereas nβ2GPI inhibited thrombin activation of FXI by 75% (P = 0.001; n = 4) (Fig. 4B ).

Fig. 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 4.

Binding of 125I-FXI to nβ2GPI, cnβ2GPI, and BSA (A), and activation of FXI (B) by thrombin in the presence of nβ2GPI and cnβ2GPI. The amount of 125I-FXI bound and FXIa generated are expressed in pmol.

β2GPI Inhibits Activation of FXI in Human Plasma. 125I-FXI was rapidly activated in β2GPI-deficient human plasma and 27.1 ± 0.01% (mean ± SD; n = 3) of total 125I-FXI added converted to FXIa in the first 4 min. However, in β2GPI-deficient plasma reconstituted with β2GPI, 125I-FXIa generation was significantly slower (15.1 ± 1.74% of total 125I-FXI; mean ± SD; n = 3) than in β2GPI-deficient plasma (Fig. 5 A and B ) (P = 0.01).

Fig. 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 5.

Activation of 125I-FXI in β2GPI-deficient human plasma. β2GPI-deficient human plasma was reconstituted by the addition of rhβ2GPI (▪) or BSA (□), and 125I-FXI was added. (A) Autoradiograph. This is a representative example of three different experiments. (B) FXIa generated expressed in fmol.

β2GPI Inhibits Activation of FXI by Thrombin and FXIIa but Does Not Bind to DS. The ability of β2GPI to inhibit activation of FXI by thrombin or FXIIa in the presence of DS was not overcome by increasing the DS concentration (data not shown). This result suggested that β2GPI does not inhibit FXI activation by competing for binding to DS. β2GPI bound to the anti-β2GPI antibody moAb1 but not DS in saturation binding experiments and in direct binding experiments bound PS but not DS or BSA (Fig. 6 A and B ).

Fig. 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 6.

(A) Saturation binding of 125I-rhβ2GPI to DS and moAb1 to β2GPI. Saturation binding of 125I-rhβ2GPI (1.56-200 nM) to immobilized moAb1 (▴), DS (▾), and BSA (▪) was performed as indicated in Methods. (B) Direct Binding of 125I-rhβ2GPI to microtiter wells coated with PS, DS, or BSA. The amount of 125I-rhβ2GPI bound was determined as described in Methods.

Discussion

Although the physiological function of β2GPI has not been deduced, plasma from β2GPI null mice exhibits significantly diminished in vitro thrombin generation compared with plasma from β2GPI wild-type mice (18), implying that β2GPI may have an important in vivo role in the generation of thrombin. We have examined the interaction between β2GPI and FXI in the context of previous studies showing that β2GPI inhibits the contact activation pathway and other downstream coagulation reactions including the generation of FXa. We report that β2GPI binds FXI and inhibits its activation to FXIa by thrombin and FXIIa. Inhibition of FXI activation occurred in the presence of DS and was demonstrated with concentrations of β2GPI much lower than normally found in human plasma. The inhibition was dose-dependent and reached 100% at 10 μM.

The C-terminal loop region of β2GPI is surface exposed and is susceptible to cleavage by the proteases plasmin and FXa. Cleavage at Lys-317-Thr-318 of the polypeptide chain exists with the two cleaved segments linked by a disulphide bonded complex (7). This cleavage alters the spatial array of the three critical Lys residues and abolishes the ability of β2GPI to bind anionic phospholipid surfaces (7). It has previously been reported that cleavage of β2GPI at Lys-317-Thr-318 disturbs the nearby electrostatic environment (37). It is believed that the integrity of the 317/318 peptide bond is important in tethering the cluster of positively charged and hydrophobic residues in this region. Although the hydrophobic C-terminal loop is important in phospholipid binding, a preparation of nβ2GPI cleaved at Lys-317-Thr-318 by plasmin bound to FXI just as well as nβ2GPI but did not inhibit the activation of FXI by thrombin (Fig. 4 A and B ).

β2GPI is often clipped at Lys-317-Thr-318 in plasma of patients with lupus anticoagulant and in disseminated intravascular coagulation (DIC) (12,13). The clipped form of β2GPI correlated with in vitro markers of fibrinolytic activity. Thus, in vivo the clipped form is most likely generated by plasmin. The C-terminal hydrophobic loop of cβ2GPI has been confirmed by heteronuclear magnetic resonance to be tightly fixed by electrostatic interaction with the lysine cluster at the phospholipid binding site while at the same time enhancing stability and neutralizing the positive charge in this region (37). Thus, the C-terminal loop of the intact β2GPI is more mobile than that of the clipped molecule, allowing a better interaction with FXI/thrombin complexes, which may explain why cβ2GPI binds FXI but does not inhibit its activation by thrombin.

Both β2GPI and FXI contain protein modules. In FXI these consist of ≈90 amino acids each, are located at the N terminus, and are commonly termed apple domains. The apple domains mediate binding with other proteins and proteoglycans. Although this study did not investigate domain-specific interactions between FXI and β2GPI, we noted that the interaction was not affected by HK (data not shown), suggesting that HK and β2GPI bind to different sites on FXI. There was no binding of HK to β2GPI (data not shown).

Platelet-bound FXIa converts FIX by proteolytic cleavage to its active form, FIXa. FIX is a zymogen form of a protease critical to regulation of blood coagulation (38) that may also be activated by the complex of tissue factor with FVIIa (39,40). FXI circulates in human plasma as a covalent dimer of two identical 80-kDa molecules and lacks the Gla domain that is characteristic of plasma coagulation proteases (41). It has been proposed that FXI functions by binding the catalytic surface of platelets with one polypeptide, whereas the other polypeptide interacts with FIX (42). Clotting factors that are protease zymogens such as FIX are typically activated in the presence of a protein cofactor plus divalent cations and an appropriate procoagulant phospholipid surface. Interestingly, no protein cofactor has been identified that is required for FIX activation, and its activation is not influenced by the addition of phospholipid.

β2GPI at physiological concentrations has been demonstrated to inhibit the generation of FXa in the presence of activated gel filtered platelets (19). Activated platelets provide an appropriate in vivo procoagulant surface for assembly of surface-bound protease substrate complexes. Moreover, activated platelets rather than endothelial cells are the preferred procoagulant surface for binding and activating FXI, which is critical for the initiation of the consolidation phase of coagulation (41). FXI/FXIa binds activated platelets in a saturable and reversible manner in the presence of either HK and zinc ions (43, 44) or prothrombin and calcium ions (45). Platelet-bound FXI can be activated by FXIa, thrombin, or FXIIa, although the preferred in vivo activator is most likely thrombin (41). Thus, activation of FXI on activated platelet surfaces by thrombin accelerates coagulation by the sequential activation of FIXa and FXa.

The effect of β2GPI on FXI activation by thrombin and FXIIa has major implications for understanding the role of β2GPI in coagulation and the prothrombotic diathesis seen in patients with APS. Whereas β2GPI inhibits generation of FXa on activated platelets, antiphospholipid antibodies are known to interfere with this inhibition, thereby increasing FXa generation (19). Inhibition of FXI activation by β2GPI using a system with purified coagulation factors and in human β2GPI-deficient plasma provides a regulatory mechanism for FXa and thrombin generation in vivo. The demonstration that β2GPI binds FXI and inhibits its activation by thrombin and FXIIa provides a possible alternative explanation for the thrombosis in patients with APS. Specifically, antiphospholipid antibodies that generally have low affinity for antigen may efficiently bind platelet-associated β2GPI, thereby blocking its attenuating effect on FXI activation.

Although FXI is not essential for haemostasis, unlike coagulation factors of the extrinsic and common pathways, FXI activity is essential for certain in vivo thrombosis models in rabbits (46) and mice (47), as well as in the early postnatal mortality observed in protein C-deficient mice (48). In a recent report, FXI was demonstrated to be essential for thrombus propagation in a primate arterial thrombosis model (49). In that study, the authors concluded that extension of thrombi in vivo was dependent on the activation of FXI. Interestingly, elevated levels of FXI have been reported to be an independent risk factor for both venous and arterial thrombosis in humans (45,46).

We have demonstrated that β2GPI can bind FXI and inhibit the activation of FXI by thrombin and FXIIa. Secondly, we have demonstrated that cnβ2GPI can bind FXI but does not inhibit its activation by thrombin. We propose that β2GPI is a physiological inhibitor of FXI activation in vivo and that cnβ2GPI is part of the positive feedback loop in FXI activation.

We propose that this interaction may be important in vivo and that the inhibition of this effect by antiphospholipid antibodies may be an important mechanism for thrombosis in patients with APS.

Acknowledgments

We thank Dr. Richard Smart for assistance with iodination and Ms. Alexandra de Nangle for expert secretarial assistance in preparation of the manuscript. This study was supported by a grant from the National Health and Medical Research Council of Australia.

Footnotes

  • ↵ ‡ To whom correspondence should be addressed at: Department of Immunology, Allergy, and Infectious Diseases, St. George Hospital, University of New South Wales, 2 South Street, Kogarah 2217, Australia. E-mail: s.krilis{at}unsw.edu.au.

  • Abbreviations: APS, antiphospholipid syndrome; cnβ2GPI, clipped native β2GPI; DS, dextran sulfate; FX, FXI, and FXII, factor X, XI, and XII; GPI, glycoprotein I; HK, high molecular weight kininogen; nβ2GPI, native β2GPI; PS, phosphatidylserine; rhβ2GPI, recombinant human β2GPI.

  • Copyright © 2004, The National Academy of Sciences

References

  1. ↵
    Polz, E. & Kostner, G. M. (1979) FEBS Lett. 102 , 183-186. pmid:222615
    OpenUrlCrossRefPubMed
  2. Steinkasserer, A., Estaller, C., Weiss, E. H., Sim, R. B. & Day, A. J. (1991) Biochem. J. 277 , 387-391. pmid:1650181
  3. Lozier, J., Takahashi, N. & Putnam, F. W. (1984) Proc. Natl. Acad. Sci. USA 81 , 3640-3644. pmid:6587378
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Reid, K. B. & Day, A. J. (1989) Immunol. Today 10 , 177-180. pmid:2751824
    OpenUrlCrossRefPubMed
  5. ↵
    Steinkasserer, A., Barlow, P. N., Willis, A. C., Kertesz, Z., Campbell, I. D., Sim, R. B. & Norman, D. G. (1992) FEBS Lett. 313 , 193-197. pmid:1426288
    OpenUrlCrossRefPubMed
  6. ↵
    Kandiah, D. A., Sali, A., Sheng, Y., Victoria, E. J., Marquis, D. M., Coutts, S. M. & Krilis, S. A. (1998) Adv. Immunol. 70 , 507-563. pmid:9755344
    OpenUrlCrossRefPubMed
  7. ↵
    Hunt, J. E., Simpson, R. J. & Krilis, S. A. (1993) Proc. Natl. Acad. Sci. USA 90 , 2141-2145. pmid:8460120
    OpenUrlAbstract/FREE Full Text
  8. Hunt, J. & Krilis, S. (1994) J. Immunol. 152 , 653-659. pmid:7506730
    OpenUrlAbstract
  9. ↵
    Sheng, Y., Sali, A., Herzog, H., Lahnstein, J. & Krilis, S. A. (1996) J. Immunol. 157 , 3744-3751. pmid:8871678
    OpenUrlAbstract
  10. ↵
    Guerin, J., Sheng, Y., Reddel, S., Iverson, G. M., Chapman, M. G. & Krilis, S. A. (2002) J. Biol. Chem. 277 , 2644-2649. pmid:11711550
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Ohkura, N., Hagihara, Y., Yoshimura, T., Goto, Y. & Kato, H. (1998) Blood 91 , 4173-4179. pmid:9596664
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Horbach, D. A., van Oort, E. T., Lisman, T., Meijers, J. C., Derksen, R. H. & de Groot, P. G. (1999) Thromb. Haemostasis 81 , 87-95. pmid:10348717
    OpenUrlPubMed
  13. ↵
    Itoh, Y., Inuzuka, K., Kohno, I., Wada, H., Shiku, H., Ohkura, N. & Kato, H. (2000) J. Biochem. (Tokyo) 128 , 1017-1024. pmid:11098145
    OpenUrlCrossRefPubMed
  14. ↵
    McNeil, H. P., Simpson, R. J., Chesterman, C. N. & Krilis, S. A. (1990) Proc. Natl. Acad. Sci. USA 87 , 4120-4124. pmid:2349221
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Galli, M., Comfurius, P., Maassen, C., Hemker, H. C., de Baets, M. H., van Breda-Vriesman, P. J., Barbui, T., Zwaal, R. F. & Bevers, E. M. (1990) Lancet 335 , 1544-1547. pmid:1972485
    OpenUrlCrossRefPubMed
  16. ↵
    McNeil, H. P., Chesterman, C. N. & Krilis, S. A. (1991) Adv. Immunol. 49 , 193-280. pmid:1853785
    OpenUrlCrossRefPubMed
  17. ↵
    Reddel, S. W. & Krilis, S. A. (2002) The Molecular Pathology of Autoimmune Diseases, eds. Theofilopoulos, A. & Bona, C. A. (Taylor and Francis, New York), 2nd Ed., pp. 325-352.
  18. ↵
    Sheng, Y., Reddel, S. W., Herzog, H., Wang, Y. X., Brighton, T., France, M. P., Robertson, S. A. & Krilis, S. A. (2001) J. Biol. Chem. 276 , 13817-13821. pmid:11145969
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Shi, W., Chong, B. H., Hogg, P. J. & Chesterman, C. N. (1993) Thromb. Haemostasis 70 , 342-345. pmid:8236146
    OpenUrlPubMed
  20. ↵
    Nimpf, J., Bevers, E. M., Bomans, P. H., Till, U., Wurm, H., Kostner, G. M. & Zwaal, R. F. (1986) Biochim. Biophys. Acta 884 , 142-149. pmid:3768409
    OpenUrlPubMed
  21. ↵
    Nimpf, J., Wurm, H. & Kostner, G. M. (1987) Atherosclerosis 63 , 109-114. pmid:3827975
    OpenUrlCrossRefPubMed
  22. ↵
    Mori, T., Takeya, H., Nishioka, J., Gabazza, E. C. & Suzuki, K. (1996) Thromb. Haemostasis 75 , 49-55. pmid:8713779
    OpenUrlPubMed
  23. ↵
    Nakaya, Y., Schaefer, E. J. & Brewer, H. B., Jr. (1980) Biochem. Biophys. Res. Commun. 95 , 1168-1172. pmid:7417307
    OpenUrlCrossRefPubMed
  24. ↵
    Manfredi, A. A., Rovere, P., Heltai, S., Galati, G., Nebbia, G., Tincani, A., Balestrieri, G. & Sabbadini, M. G. (1998) Arthritis Rheum. 41 , 215-223. pmid:9485079
    OpenUrlCrossRefPubMed
  25. ↵
    Colman, R. W. (2000) Hemostasis and Thrombosis: Basic Principles and Clinical Practice, eds. Colman, R. W., Hirsh, J., Marder, V. J., Clowes, A. W. & George, G. N. (Lippincott Williams & Wilkins, Philadelphia), pp. 103-122.
  26. ↵
    Schousboe, I. & Rasmussen, M. S. (1995) Thromb. Haemostasis 73 , 798-804. pmid:7482406
    OpenUrlPubMed
  27. ↵
    Schousboe, I. (1985) Blood 66 , 1086-1091. pmid:4052628
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Wurm, H., Beubler, E., Polz, E., Holasek, A. & Kostner, G. (1982) Metabolism 31 , 484-486. pmid:7078428
    OpenUrlCrossRefPubMed
  29. ↵
    Iverson, G. M., Reddel, S. W., Victoria, E. J., Cockerill, K. A., Wang, Y. X., Marti-Renom, M. A., Sali, A., Marquis, D. M., Krilis, S. A. & Linnik, M. D. (2002) J. Immunol. 169 , 7097-7103. pmid:12471146
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Baird, T. R. & Walsh, P. N. (2002) J. Biol. Chem. 277 , 28498-28503. pmid:12029092
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Renne, T., Gailani, D., Meijers, J. C. & Muller-Esterl, W. (2002) J. Biol. Chem. 277 , 4892-4899. pmid:11733491
    OpenUrlAbstract/FREE Full Text
  32. ↵
    Baglia, F. A. & Walsh, P. N. (2000) J. Biol. Chem. 275 , 20514-20519. pmid:10781579
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Scott, C. F. & Colman, R. W. (1992) Proc. Natl. Acad. Sci. USA 89 , 11189-11193. pmid:1454798
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Brunnee, T., La Porta, C., Reddigari, S. R., Salerno, V. M., Kaplan, A. P. & Silverberg, M. (1993) Blood 81 , 580-586. pmid:8427954
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Sheng, Y., Hanly, J. G., Reddel, S. W., Kouts, S., Guerin, J., Koike, T., Ichikawa, K., Sturgess, A. & Krilis, S. A. (2001) Clin. Exp. Immunol. 124 , 502-508. pmid:11472415
    OpenUrlCrossRefPubMed
  36. ↵
    Thompson, R. E., Mandle, R., Jr. & Kaplan, A. P. (1977) J. Clin. Invest. 60 , 1376-1380. pmid:915004
    OpenUrlCrossRefPubMed
  37. ↵
    Hoshino, M., Hagihara, Y., Nishii, I., Yamazaki, T., Kato, H. & Goto, Y. (2000) J. Mol. Biol. 304 , 927-939. pmid:11124037
    OpenUrlCrossRefPubMed
  38. ↵
    Davie, E. W., Fujikawa, K. & Kisiel, W. (1991) Biochemistry 30 , 10363-10370. pmid:1931959
    OpenUrlCrossRefPubMed
  39. ↵
    Di Scipio, R. G., Kurachi, K. & Davie, E. W. (1978) J. Clin. Invest. 61 , 1528-1538. pmid:659613
    OpenUrlCrossRefPubMed
  40. ↵
    Osterud, B. & Rapaport, S. I. (1977) Proc. Natl. Acad. Sci. USA 74 , 5260-5264. pmid:271951
    OpenUrlAbstract/FREE Full Text
  41. ↵
    Walsh, P. N. (2001) Thromb. Haemostasis 86 , 75-82. pmid:11487044
    OpenUrlPubMed
  42. ↵
    Gailani, D., Ho, D., Sun, M. F., Cheng, Q. & Walsh, P. N. (2001) Blood 97 , 3117-3122. pmid:11342438
    OpenUrlAbstract/FREE Full Text
  43. ↵
    Greengard, J. S., Heeb, M. J., Ersdal, E., Walsh, P. N. & Griffin, J. H. (1986) Biochemistry 25 , 3884-3890. pmid:3017409
    OpenUrlCrossRefPubMed
  44. ↵
    Sinha, D., Seaman, F. S., Koshy, A., Knight, L. C. & Walsh, P. N. (1984) J. Clin. Invest. 73 , 1550-1556. pmid:6609936
    OpenUrlCrossRefPubMed
  45. ↵
    Baglia, F. A. & Walsh, P. N. (1998) Biochemistry 37 , 2271-2281. pmid:9485373
    OpenUrlCrossRefPubMed
  46. ↵
    Minnema, M. C., Friederich, P. W., Levi, M., von dem Born, P. A., Mosnier, L. O., Meijers, J. C., Biemond, B. J., Hack, C. E., Bouma, B. N. & ten Cate, H. (1998) J. Clin. Invest. 101 , 10-14. pmid:9421460
    OpenUrlCrossRefPubMed
  47. ↵
    Rosen, E. D., Gailani, D. & Castellino, F. J. (2002) Thromb. Haemostasis 87 , 774-776. pmid:12008966
    OpenUrlPubMed
  48. ↵
    Chan, J. C., Ganopolsky, J. G., Cornelissen, I., Suckow, M. A., Sandoval-Cooper, M. J., Brown, E. C., Noria, F., Gailani, D., Rosen, E. D., et. al. (2001) Am. J. Pathol. 158 , 469-479. pmid:11159184
    OpenUrlCrossRefPubMed
  49. ↵
    Gruber, A. & Hanson, S. R. (2003) Blood 102 , 953-955. pmid:12689935
    OpenUrlAbstract/FREE Full Text
  50. Meijers, J. C., Tekelenburg, W. L., Bouma, B. N., Bertina, R. M. & Rosendaal, F. R. (2000) N. Engl. J. Med. 342 , 696-701. pmid:10706899
    OpenUrlCrossRefPubMed
  51. Berliner, J. I., Rybicki, A. C., Kaplan, R. C., Monrad, E. S., Freeman, R. & Billett, H. H. (2002) Thromb. Res. 107 , 55-60. pmid:12413590
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Article Alerts
Email Article

Thank you for your interest in spreading the word on PNAS.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
β2-Glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: Loss of inhibition by clipped β2-glycoprotein I
(Your Name) has sent you a message from PNAS
(Your Name) thought you would like to see the PNAS web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
β2-Glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: Loss of inhibition by clipped β2-glycoprotein I
Tong Shi, G. Michael Iverson, Jian C. Qi, Keith A. Cockerill, Matthew D. Linnik, Pamela Konecny, Steven A. Krilis
Proceedings of the National Academy of Sciences Mar 2004, 101 (11) 3939-3944; DOI: 10.1073/pnas.0400281101

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
β2-Glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: Loss of inhibition by clipped β2-glycoprotein I
Tong Shi, G. Michael Iverson, Jian C. Qi, Keith A. Cockerill, Matthew D. Linnik, Pamela Konecny, Steven A. Krilis
Proceedings of the National Academy of Sciences Mar 2004, 101 (11) 3939-3944; DOI: 10.1073/pnas.0400281101
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Mendeley logo Mendeley
Proceedings of the National Academy of Sciences of the United States of America: 101 (11)
Table of Contents

Submit

Sign up for Article Alerts

Jump to section

  • Article
    • Abstract
    • Experimental Procedures
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & SI
  • Info & Metrics
  • PDF

You May Also be Interested in

Water from a faucet fills a glass.
News Feature: How “forever chemicals” might impair the immune system
Researchers are exploring whether these ubiquitous fluorinated molecules might worsen infections or hamper vaccine effectiveness.
Image credit: Shutterstock/Dmitry Naumov.
Reflection of clouds in the still waters of Mono Lake in California.
Inner Workings: Making headway with the mysteries of life’s origins
Recent experiments and simulations are starting to answer some fundamental questions about how life came to be.
Image credit: Shutterstock/Radoslaw Lecyk.
Cave in coastal Kenya with tree growing in the middle.
Journal Club: Small, sharp blades mark shift from Middle to Later Stone Age in coastal Kenya
Archaeologists have long tried to define the transition between the two time periods.
Image credit: Ceri Shipton.
Mouse fibroblast cells. Electron bifurcation reactions keep mammalian cells alive.
Exploring electron bifurcation
Jonathon Yuly, David Beratan, and Peng Zhang investigate how electron bifurcation reactions work.
Listen
Past PodcastsSubscribe
Panda bear hanging in a tree
How horse manure helps giant pandas tolerate cold
A study finds that giant pandas roll in horse manure to increase their cold tolerance.
Image credit: Fuwen Wei.

Similar Articles

Site Logo
Powered by HighWire
  • Submit Manuscript
  • Twitter
  • Facebook
  • RSS Feeds
  • Email Alerts

Articles

  • Current Issue
  • Special Feature Articles – Most Recent
  • List of Issues

PNAS Portals

  • Anthropology
  • Chemistry
  • Classics
  • Front Matter
  • Physics
  • Sustainability Science
  • Teaching Resources

Information

  • Authors
  • Editorial Board
  • Reviewers
  • Subscribers
  • Librarians
  • Press
  • Cozzarelli Prize
  • Site Map
  • PNAS Updates
  • FAQs
  • Accessibility Statement
  • Rights & Permissions
  • About
  • Contact

Feedback    Privacy/Legal

Copyright © 2021 National Academy of Sciences. Online ISSN 1091-6490